16. Crow-Fukase syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 16 / Drugs : 17 - (DrugBank : 8) / Drug target genes : 5 - Drug target pathways : 79
Crow-Fukase syndrome and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
| ID | Diseases (Sorted by score) | Score |
|---|---|---|
| 16 | Crow-Fukase syndrome | - |
| 49 | Systemic lupus erythematosus | 5.000 |
| 28 | Systemic amyloidosis | 5.000 |
| 331 | Idiopathic multicentric castleman disease | 3.303 |
| 26 | HTLV-1-associated myelopathy | 3.284 |
| 51 | Scleroderma | 3.228 |
| 46 | Malignant rheumatoid arthritis | 3.217 |
| 13 | Multiple sclerosis | 3.212 |
| 38 | Stevens-Johnson syndrome | 2.040 |
| 45 | Eosinophilic granulomatosis with Polyangiitis | 2.000 |
| 283 | Acquired pure red cell aplasia | 2.000 |
| 284 | Diamond-Blackfan anemia | 1.964 |
| 35 | Pemphigus | 1.964 |
| 40 | Takayasu arteritis | 1.944 |
| 61 | Autoimmune hemolytic anemia | 1.944 |
| 42 | Polyarteritis nodosa | 1.938 |
| 285 | Fanconi anemia | 1.920 |
| 41 | Giant cell arteritis | 1.909 |
| 228 | Bronchiolitis obliterans | 1.909 |
| 164 | Oculocutaneous albinism | 1.906 |
| 66 | IgA nephropathy | 1.903 |
| 60 | Aplastic anemia | 1.886 |
| 11 | Myasthenia gravis | 1.880 |
| 63 | Idiopathic thrombocytopenic purpura | 1.880 |
| 222 | Primary nephrotic syndrome | 1.859 |
| 19 | Lysosomal storage disease | 1.852 |
| 65 | Primary immunodeficiency | 1.840 |
| 85 | Idiopathic interstitial pneumonia | 1.836 |
| 96 | Crohn disease | 1.821 |
| 2 | Amyotrophic lateral sclerosis | 1.821 |
| 25 | Progressive multifocal leukoencephalopathy | 1.143 |
| 39 | Toxic epidermal necrolysis | 1.018 |
| 220 | Rapidly progressive glomerulonephritis | 1.000 |
| 30 | Distal myopathy | 1.000 |